Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma

被引：1

作者：

Mizumura, Kenji ^{[1
]}

Gon, Yasuhiro ^{[1
]}

Harada, Norihiro ^{[2
,3
]}

Yamada, Shiho ^{[1
]}

Fukuda, Asami ^{[1
]}

Ozoe, Ryosuke ^{[1
]}

Maruoka, Shuichiro ^{[1
]}

Abe, Sumiko ^{[2
,3
]}

Takahashi, Kazuhisa ^{[2
,3
]}

Tanaka, Akihiko ^{[4
]}

Sagara, Hironori ^{[4
]}

Akamatsu, Taisuke ^{[5
]}

Shirai, Toshihiro ^{[5
]}

Masaki, Katsunori ^{[6
]}

Fukunaga, Koichi ^{[6
]}

Kobayashi, Konomi ^{[7
]}

Nagase, Hiroyuki ^{[7
]}

Miyahara, Nobuaki ^{[8
]}

Kanehiro, Arihiko ^{[9
]}

Kitamura, Noboru ^{[10
]}

Sugihara, Naruhiko ^{[10
]}

Kumasawa, Fumio ^{[1
,11
]}

Terada-Hirashima, Junko ^{[12
]}

Hojo, Masayuki ^{[12
]}

Chibana, Kazuyuki ^{[13
]}

Tagaya, Etsuko ^{[14
]}

机构：

[1] Nihon Univ, Sch Med, Dept Internal Med, Div Resp Med, 30-1 Oyaguchi Kami Cho,Itabashi Ku, Tokyo 1738610, Japan

[2] Juntendo Univ, Fac Med, Dept Resp Med, Tokyo, Japan

[3] Juntendo Univ, Grad Sch Med, Tokyo, Japan

[4] Showa Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo, Japan

[5] Shizuoka Prefectural Gen Hosp, Dept Resp Med, Shizuoka, Japan

[6] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo, Japan

[7] Teikyo Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo, Japan

[8] Okayama Univ, Dept Med Technol, Acad Field Hlth Sci, Okayama, Japan

[9] St Francis Himeji St Marys Hosp, Social Med Corp Fdn, Himeji, Hyogo, Japan

[10] Jinyu Clin, Tokyo, Japan

[11] Akabane Cent Gen Hosp, Div Resp Med, Tokyo, Japan

[12] Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan

[13] Dokkyo Med Univ, Sch Med, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan

[14] Tokyo Womens Med Univ, Dept Resp Med, Tokyo, Japan

来源：

ALLERGOLOGY INTERNATIONAL | 2025年 / 74卷 / 01期

关键词：

Asthma; Dupilumab; Eosinophil; Fractional exhaled nitric oxide; Sputum; TO-SEVERE ASTHMA; VALIDATION; HYPERSECRETION; EFFICACY; AIR;

D O I：

10.1016/j.alit.2024.08.005

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Background: The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. Methods: This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. Results: Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV1, and CASA-Q scores. FEV1 improvement was correlated with enhancement in the sputum domain of the CASA-Q. Patients exhibiting elevated FeNO levels and blood eosinophil counts demonstrated more significant enhancements in FEV1. CASA-Q sputum domain scores were significantly higher in the group with elevated eosinophil counts. Regression analysis revealed that FeNO levels and blood eosinophil counts are significant predictors of FEV1 improvement, with blood eosinophil counts also predicting sputum improvement in patients treated with dupilumab. Conclusions: Type-2 biomarkers may act as indicators of improvement in FEV1 and sputum outcomes among patients with severe asthma undergoing dupilumab treatment in real-world settings. (c) 2024 Japanese Society of Allergology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：144 / 155

页数：12

共 50 条

[21] Evaluation of the efficacy and predictive factors of dupilumab for cough and sputum in severe asthma: A real-world study
Ozoe, Ryosuke
Mizumura, Kenji
Yamada, Shiho
Fukuda, Asami
Maruoka, Shuichiro
Gon, Yasuhiro
RESPIROLOGY, 2024, 29 : 99 - 99
[22] A real-world study of symptomatic eosinophilia in moderate-to-severe asthma patients on dupilumab therapy
Fisch, Matthew
Fajt, Merritt L.
Wenzel, Sally E.
Petrov, Andrej A.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (08): : 2183 - 2186
[23] Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
Barnes, Neil
Menzies-Gow, Andrew
Mansur, Adel H.
Spencer, David
Percival, Fran
Radwan, Amr
Niven, Rob
JOURNAL OF ASTHMA, 2013, 50 (05) : 529 - 536
[24] The Real-world Effectiveness of Tezepelumab in a Cohort of Patients with Severe Asthma
Nopsopon, Tanawin
Brown, Alyson
Akenroye, Ayobami
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB96 - AB96
[25] The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
Ibrahim, H.
O'Sullivan, R.
Casey, D.
Murphy, J.
MacSharry, J.
Plant, B. J.
Murphy, D. M.
RESPIRATORY RESEARCH, 2019, 20 (01)
[26] The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
H. Ibrahim
R. O’Sullivan
D. Casey
J. Murphy
J. MacSharry
B. J. Plant
D. M. Murphy
Respiratory Research, 20
[27] Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
Subramaniam, Abirami
Mulligan, Emma
Lane, Stephen
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[28] Real-world Effectiveness of Dupilumab in Biologic Naive Patients With Asthma: Analysis From the US Advantage Study
Stanford, R. H.
Blaiss, M.
Bleecker, E. R.
Jacob-Nara, J. A.
Duh, M.
Wang, Z.
Soler, X.
Hardin, M. E.
Ye, M.
Nair, R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[29] Dupilumab Real-world Effectiveness (RWE) in Reducing Healthcare Resource Utilization Among Moderate-to-Severe Asthma Patients
Modena, B. D.
Pawar, A.
Blaiss, M. S.
Khan, A.
Gomez, L. De Prado
Zhang, Y.
Radwan, A.
Jacob-Nara, J. A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[30] Real-world effectiveness (RWE) of dupilumab in reducing healthcare resource utilization among moderate-to-severe asthma patients
Pawar, A.
Blaiss, M. S.
Modena, B. D.
Khan, A. H.
Gomez, L. De Prado
Zhang, Y.
Siddiqui, S.
Jacob-Nara, J. A.
Gomez, L. De Prado
EUROPEAN RESPIRATORY JOURNAL, 2022, 60

← 1 2 3 4 5 →